Spots Global Cancer Trial Database for Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immunotherapy of Hepatocellular Carcinoma With Gamma Delta T Cells
Official Title: Immunotherapy of Hepatocellular Carcinoma by Hepatic Intra Arterial Injection of Autologous Gamma-delta T Lymphocytes: A Phase I Study
Study ID: NCT00562666
Conditions
Interventions
Study Description
Brief Summary: For most patients with hepatocellular carcinoma, surgery or other curative procedures are not possible and only palliative measures could be applied (chemoembolization, targeted drugs, best supportive cares, etc). In the ICAR study, increasing doses of a cell therapy product will be evaluated in patients in a palliative setting. All patients will have one hepatic intra-arterial injection of immunological cells (gamma-delta T lymphocytes) and will be evaluated for safety.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Unité de Thérapie Cellulaire, Laboratoire de Cytogénétique et Biologie Cellulaire, CHU Rennes, Rennes, , France
Département d'Oncologie Médicale - CRLCC Eugène Marquis, Rennes, , France
Service de Chirugie Viscérale - Hôpital de Pontchaillou, Rennes, , France
Contact Details
Name: Jean-Luc RAOUL, MD, PhD
Affiliation: CRLCC Eugène Marquis, Rennes
Role: PRINCIPAL_INVESTIGATOR
Name: Eric BELLISSANT, MD, PhD
Affiliation: Rennes University Hospital
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
